• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌健康状态效用的评估。

Estimation of health state utilities in breast cancer.

作者信息

Kim Seon-Ha, Jo Min-Woo, Ock Minsu, Lee Hyeon-Jeong, Lee Jong-Won

机构信息

Department of Nursing, College of Nursing, Dankook University, Cheonan.

Department of Preventive Medicine, University of Ulsan College of Medicine, Seoul.

出版信息

Patient Prefer Adherence. 2017 Mar 14;11:531-536. doi: 10.2147/PPA.S129856. eCollection 2017.

DOI:10.2147/PPA.S129856
PMID:28352159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5359127/
Abstract

PURPOSE

The aim of this study is to determine the utility of breast cancer health states using the standard gamble (SG) and visual analog scale (VAS) methods in the Korean general population.

MATERIALS AND METHODS

Eight hypothetical breast cancer health states were developed based on patient education material and previous publications. Data from 509 individuals from the Korean general population were used to evaluate breast cancer health states using the VAS and the SG methods, which were obtained via computer-assisted personal interviews. Mean utility values were calculated for each human papillomavirus (HPV)-related health state.

RESULTS

The rank of health states was identical between two valuation methods. SG values were higher than VAS values in all health states. The utility values derived from SG were 0.801 (noninvasive breast cancer with mastectomy and followed by reconstruction), 0.790 (noninvasive breast cancer with mastectomy only), 0.779 (noninvasive breast cancer with breast-conserving surgery and radiation therapy), 0.731 (invasive breast cancer with surgery, radiation therapy, and/or chemotherapy), 0.610 (locally advanced breast cancer with radical mastectomy with radiation therapy), 0.587 (inoperable locally advanced breast cancer), 0.496 (loco-regional recurrent breast cancer), and 0.352 (metastatic breast cancer).

CONCLUSION

Our findings might be useful for economic evaluation of breast cancer screening and interventions in general populations.

摘要

目的

本研究旨在通过标准博弈法(SG)和视觉模拟评分法(VAS)来确定韩国普通人群中乳腺癌健康状态的效用。

材料与方法

基于患者教育材料和以往出版物开发了8种假设的乳腺癌健康状态。来自韩国普通人群的509名个体的数据用于通过计算机辅助个人访谈获得的VAS和SG方法评估乳腺癌健康状态。计算了每个人乳头瘤病毒(HPV)相关健康状态的平均效用值。

结果

两种评估方法对健康状态的排序相同。在所有健康状态下,SG值均高于VAS值。SG得出的效用值分别为0.801(乳房切除术后重建的非浸润性乳腺癌)、0.790(仅行乳房切除术的非浸润性乳腺癌)、0.779(保乳手术加放射治疗的非浸润性乳腺癌)、0.731(手术、放射治疗和/或化疗的浸润性乳腺癌)、0.610(根治性乳房切除术加放射治疗的局部晚期乳腺癌)、0.587(不可手术的局部晚期乳腺癌)、0.496(局部区域复发性乳腺癌)和0.352(转移性乳腺癌)。

结论

我们的研究结果可能有助于对普通人群中的乳腺癌筛查和干预措施进行经济评估。

相似文献

1
Estimation of health state utilities in breast cancer.乳腺癌健康状态效用的评估。
Patient Prefer Adherence. 2017 Mar 14;11:531-536. doi: 10.2147/PPA.S129856. eCollection 2017.
2
Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.基于疾病严重程度的韩国肺癌相关健康状态效用权重评估。
BMC Cancer. 2018 Nov 8;18(1):1081. doi: 10.1186/s12885-018-4960-y.
3
Estimation of Utility Weights for Prostate-related Health States in Korea.韩国前列腺相关健康状况效用值的评估。
J Prev Med Public Health. 2022 May;55(3):243-252. doi: 10.3961/jpmph.21.426. Epub 2022 May 4.
4
Estimation of population-based utility weights for health states of chronic kidney disease, dialysis and kidney transplantation.估算慢性肾脏病、透析和肾移植健康状况的基于人群的效用权重。
Nephrology (Carlton). 2020 Jul;25(7):544-550. doi: 10.1111/nep.13700. Epub 2020 Feb 12.
5
Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.头颈癌患者健康状态效用测量的比较
JAMA Otolaryngol Head Neck Surg. 2015 Aug;141(8):696-703. doi: 10.1001/jamaoto.2015.1314.
6
Estimation of utility weights for major liver diseases according to disease severity in Korea.根据韩国主要肝脏疾病的严重程度估算效用权重
BMC Gastroenterol. 2017 Sep 5;17(1):103. doi: 10.1186/s12876-017-0660-3.
7
Development, feasibility, and validity of a computer-based utility assessment tool for measuring asthma-specific health utilities in Malaysia using the standard gamble method.一种基于计算机的效用评估工具的开发、可行性及有效性,该工具使用标准博弈法测量马来西亚哮喘特异性健康效用。
J Asthma. 2016 Oct;53(8):835-42. doi: 10.3109/02770903.2016.1156694. Epub 2016 Apr 6.
8
Mastopexy for breast ptosis: Utility outcomes of population preferences.乳房下垂的乳房固定术:人群偏好的效用结果
Plast Surg (Oakv). 2015 Summer;23(2):103-7. doi: 10.4172/plastic-surgery.1000916.
9
Utility assessment for different clinical phases of breast cancer in Taiwan.台湾地区乳腺癌不同临床阶段的效用评估。
J Formos Med Assoc. 2000 Sep;99(9):677-83.
10
The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population.一般韩国人群中 TTO、VAS 和 EQ-5D 测量的部分性癫痫效用评分。
Epilepsy Res. 2014 Jul;108(5):963-71. doi: 10.1016/j.eplepsyres.2014.02.014. Epub 2014 Mar 12.

引用本文的文献

1
Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA.阿那曲唑预防绝经后高危女性乳腺癌:英国和美国的成本效益分析。
BMC Health Serv Res. 2024 Feb 13;24(1):198. doi: 10.1186/s12913-024-10658-0.
2
Health-Related Quality of Life (HRQoL) Using EQ-5D-5L: Value Set Derived for Indian Breast Cancer Cohort.使用 EQ-5D-5L 评估健康相关生命质量(HRQoL):为印度乳腺癌队列制定的效用值。
Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1199-1207. doi: 10.31557/APJCP.2023.24.4.1199.
3
All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.所有 HER2 阴性乳腺癌患者均需要进行 gBRCA 检测:成本效益和临床获益。
Br J Cancer. 2023 Feb;128(4):638-646. doi: 10.1038/s41416-022-02111-y. Epub 2022 Dec 23.
4
Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea.韩国HR+/HER2-局部晚期或转移性乳腺癌患者治疗模式及卫生资源利用的真实世界证据研究
J Drug Assess. 2022 Aug 8;11(1):12-19. doi: 10.1080/21556660.2022.2107834. eCollection 2022.
5
Estimation of Utility Weights for Prostate-related Health States in Korea.韩国前列腺相关健康状况效用值的评估。
J Prev Med Public Health. 2022 May;55(3):243-252. doi: 10.3961/jpmph.21.426. Epub 2022 May 4.
6
Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.诊断后和治疗期间乳腺癌患者的效用值及其恶化时间。
Qual Life Res. 2022 Oct;31(10):3077-3085. doi: 10.1007/s11136-022-03157-4. Epub 2022 May 19.
7
Cost-effectiveness of Choosing Wisely guidelines for axillary observation in women older than age 70 years with hormone receptor-positive, clinically node-negative, operable breast tumors.选择明智指南在激素受体阳性、临床淋巴结阴性、可手术的 70 岁以上女性乳腺癌腋窝观察中的成本效益。
Cancer. 2022 Jun 15;128(12):2258-2268. doi: 10.1002/cncr.34207. Epub 2022 Apr 7.
8
A Systematic Literature Review of Health Utility Values in Breast Cancer.乳腺癌健康效用值的系统文献回顾
Med Decis Making. 2022 Jul;42(5):704-719. doi: 10.1177/0272989X211065471. Epub 2022 Jan 18.
9
Health state utility values by cancer stage: a systematic literature review.癌症分期的健康状态效用值:系统文献回顾。
Eur J Health Econ. 2021 Nov;22(8):1275-1288. doi: 10.1007/s10198-021-01335-8. Epub 2021 Jun 14.
10
Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.新加坡一项针对多基因风险的乳腺癌筛查计划的成本效益分析。
BMC Health Serv Res. 2021 Apr 23;21(1):379. doi: 10.1186/s12913-021-06396-2.

本文引用的文献

1
Health State Utility Assessment for Breast Cancer.乳腺癌的健康状态效用评估
Value Health Reg Issues. 2012 May;1(1):93-97. doi: 10.1016/j.vhri.2012.03.009. Epub 2012 May 25.
2
Estimation of utility weights for human papilloma virus-related health states according to disease severity.根据疾病严重程度估算人乳头瘤病毒相关健康状态的效用权重。
Health Qual Life Outcomes. 2016 Nov 28;14(1):163. doi: 10.1186/s12955-016-0566-8.
3
A structured review of health utility measures and elicitation in advanced/metastatic breast cancer.晚期/转移性乳腺癌健康效用测量与获取的结构化综述。
Clinicoecon Outcomes Res. 2016 Jun 23;8:293-303. doi: 10.2147/CEOR.S100448. eCollection 2016.
4
Validity and reliability of EQ-5D-3L for breast cancer patients in Korea.EQ-5D-3L在韩国乳腺癌患者中的效度和信度。
Health Qual Life Outcomes. 2015 Dec 23;13:203. doi: 10.1186/s12955-015-0399-x.
5
International Variation in Female Breast Cancer Incidence and Mortality Rates.女性乳腺癌发病率和死亡率的国际差异。
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1495-506. doi: 10.1158/1055-9965.EPI-15-0535. Epub 2015 Sep 10.
6
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
7
Breast cancer. Breast cancer: a world of differences.乳腺癌。乳腺癌:差异万千的领域。
Science. 2014 Mar 28;343(6178):1452-3. doi: 10.1126/science.343.6178.1452.
8
Breast cancer: trends in international incidence in men and women.乳腺癌:男性和女性国际发病率趋势。
Br J Cancer. 2014 Apr 2;110(7):1891-7. doi: 10.1038/bjc.2014.66. Epub 2014 Feb 11.
9
Psychometric properties of the EQ-5D-5L in the general population of South Korea.韩国普通人群中 EQ-5D-5L 的心理测量特性。
Qual Life Res. 2013 Oct;22(8):2245-53. doi: 10.1007/s11136-012-0331-3. Epub 2012 Dec 6.
10
Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.比较 EQ-5D-3L 和 EQ-5D-5L 在韩国癌症患者中的心理测量特性。
Qual Life Res. 2012 Aug;21(6):1065-73. doi: 10.1007/s11136-011-0018-1. Epub 2011 Sep 23.